

2024 Ludwig Retreat Posters

LUNCHTIME: 11:30 AM - 1:30 PM			
	Author	Lab	Poster title
1	Ali Amiryousefi	SORGER	Whole-slide multiplexed tissue imaging of prostate adenocarcinoma reveals distinct immune niches in high- versus low-grade tumors
2	Jia-Ren (Jerry) Lin	SORGER	Spatial and Molecular Profiling of the Tumor Microenvironment in the NeoSTAR Trial: Predictive Biomarkers and Therapeutic Response to TROP2-Directed Antibody-Drug Conjugate Therapy in Triple-Negative Breast Cancer
3	Tuulia Vallius	SORGER	Spatial profiling of tumor cell states in primary cutaneous melanoma
4	Alex Wong	SORGER	Multiplexed 3D Analysis of Immune States and Niches in Human Tissue
5	Maxime Meylan	NNIG	Decoding Spatial Patterns Promoting Immune Exclusion in Triple Negative Breast Cancer
6	Kenichi Shimada	GUERRIERO	An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer
7	Eunbee Choi	SHAPIRO	Replication Protein A (RPA) Regulation by Cyclin K-CDK12 Revealed through Synergy between Cyclin K Degradation and ATR Inhibition in Triple-Negative Breast Cancer
8	Carlos Wanderley	GUERRIERO	Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
9	Tanjina Kader	SANTAGATA	Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma
10	Nomeda Girnius	BRUGGE	Post-treatment ovarian tumor cells show interferon pathway enrichment compared to matched pre-treatment tissue
11	Jie Hao	SHAPIRO	PTEN deficiency as a predictive biomarker for response to ATR inhibition as monotherapy and in combination with PARP inhibition in BRCA-mutant ovarian cancer
12	Renyang Liu	SHAPIRO	Evaluating the therapeutic potential of casein kinase 1 alpha (CK1α) inhibitor BTX-A51 in human liposarcomas
13	Ji Seul Han	HAIGIS	Metabolic vulnerabilities of dedifferentiated liposarcoma: a fatty acid liability
14	Samantha Bevell	BERNSTEIN	Selective Targeting of MDM2-amplified tumors using MDM2-directed PROTACs
15	Karley Whalen	LANE	Targeting UFMylation in myeloid malignancies
16	Lin Han	TOTHOVA	STAG2 Mutations Drive Development of Myelodysplastic Syndromes by Promoting R-loop-Mediated Genomic Instability and Activation of cGAS-STING
17	Yoke Seng Lee	VAN GALEN	Zotatifin, the eukaryotic translation initiation factor 4A (eIF4A) inhibitor, synergizes with Venetoclax to inhibit acute myeloid leukemia cell growth
18	Nurefsan Sariipek	VAN GALEN	Early post-transplant immune dynamics predict relapse risk in patients with TP53-mutated AML
19	Roubina Tatavosian	LAHAV	The p53 Response to Radiotherapy in Intestinal Organoids
20	Okoh Frimpong	BROWN	Chemoproteomic Evaluation of ER-Targeting PROTACs in ER+ Breast Cancer
21	Nicole Traphagen	BROWN	Defining the effects of PARP inhibition on androgen receptor function in homologous recombination- proficient prostate cancer
22	Esmé Wheeler	BROWN	Defining the Mechanisms of ERα Transcription and Its Effects on Chromatin Remodeling in Breast Cancer
23	Tao Zhang	BROWN	Macrophage-derived C1q bridges apoptosis and immunosuppression in obesity
24	Capucine Héraud	JESELSON	CDK inhibitors to overcome resistance in hormone receptor positive breast cancer
25	Daniel Michaud	GUERRIERO	Characterization of Macrophages within the Hormone Receptor-Positive Breast Tumor Microenvironment using Single Cell Transcriptomics and Multiplex Immunofluorescence
26	Jenny Hogstrom	MURANEN	Cancer-associated fibroblast-secreted succinate stimulates resistance to CDK4/6-inhibitors in HR+ breast cancer

2024 Ludwig Retreat Posters

LUNCHTIME, CONTINUED			
27	Jonathan Good	VAN GALEN	Clonal Analysis of Cancer by Mitochondrial DNA Barcoding
28	Alex Tepper	SANTAGATA	Perturb-map ST: Combining Xenium spatial transcriptomics with in situ pooled-CRISPR screening for deep phenotyping of the tumor microenvironment
29	Olwyn Mahon	MITSIADES	Elucidation of cancer cell behaviours and dependencies in tissue-specific, biomechanically relevant 3D models for Cas12 CRISPR screens in epithelial tumour cells
30	Kunitoshi Chiba	ELLEDEGE	Tissue-specific combinatorial cancer mutation screen revealed genetic requirements for transformation of normal human epithelial cells in vivo.
31	Torsten Steinbrunn	MITSIADES	CRISPR-based functional genomics studies identify mechanisms of multiple myeloma (MM) cell response to vs. resistance against novel pharmacological mutant-specific KRAS inhibitors.
32	Hanna Doh	MURANEN	Elucidating the mechanistic role of the NDRG1-TGM2 interaction in DNA replication and repair
33	Nina Kozlova	MURANEN	Novel function of the n-myc downstream regulated 1 gene (ndrg1) in dna repair links pancreatic tumor stroma to chemoresistance
34	Alice Bertocchi	AGUDO	B cells facilitate lymph node colonization in pancreatic ductal adenocarcinoma
35	Megan Hoffman	DOUGAN	Eosinophils alter metastasis
36	Kayla Cruz	MURANEN	Cancer-Associated Fibroblast derived YKL-40 promotes tumor progression and immunosuppression in pancreatic cancer
37	Li Qiang	DOUGAN	Signaling pathways in tumoricidal macrophages in pancreatic cancer
38	Jiao Shen	DOUGAN	Identification of KRAS-specific TCRs from human peripheral blood
39	Lauren Hsu Pilar Baldominos	AGUDO	Control of immunosuppressive hubs in spatially heterogeneous solid cancers
40	Cameron Fraser	UBELLACKER	Inducing lipid peroxidation in lymph node cancer cells to promote a systemic anti-cancer response
41	Bryce Ordway	ELLISEN	Investigation of late recurrence reveals the direct inhibition of pyruvate kinase by s-adenosylmethionine
42	Chenxu (Vincent) Guo	ELLISEN	HD-PTP mediates tumor suppression via modulation of anti-tumor immunity
43	Ting Liu	ELLISEN	Antibody-Drug Conjugate Response and Resistance in Triple Negative Breast Cancer Revealed by Single-cell and Spatial Profiling
44	Carman Li	BRUGGE	Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer
45	Alexander Gottlieb	GUERRIERO	High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
46	Adam Nelson	GUERRIERO	Immune-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancer are overcome by addition of CSF-1R inhibition and immune checkpoint blockade

2024 Ludwig Retreat Posters

AFTERNOON, 4-6 PM			
47	Nicholas Ashton	D'ANDREA	Creating genetic models to unravel the mechanism of action of USP1-inhibitors in BRCA1-deficient cancers.
48	Mike Oliphant	BRUGGE	Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and non-carriers harbor common breast cancer copy number alterations
49	Zhaoji Liu	WULF	Plasma miRNAs associated with cisplatin sensitivity in breast cancer
50	Shuhei Asada	D'ANDREA	Defect of the Microhomology-Mediated End-Joining in Ewing Sarcoma
51	Lingli He	SCADDEN	PSTK inhibition activates cGAS-STING precipitating ferroptotic cell death in leukemic stem cells
52	Christina Mayerhofer	SCADDEN	AML can persist through chemotherapy and nutrient stress by OGFOD1 overcoming ribosome stalling
53	Ting Zhao	SCADDEN	Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming
54	Maolin Ge, Magdy Gohar	BAR-PELED	Systematic identification of thiol-reductive stress targets uncovers a mitochondrial dependency
55	Junbing Zhang, Yousuf Ali	BAR-PELED	Oxidation of retromer complex controls mitochondrial translation
56	Tashbib Khan	TOKER	Understanding and targeting glycogen metabolism in PI3K/AKT pathway-driven cancer
57	Josefina Mendez	TOKER	BET bromodomain-containing protein BRD2 is a targetable vulnerability in cancer
58	Gilbert Salloum	TOKER	Integrin signaling is a targetable vulnerability in ovarian cancer with hyperactivated AKT
59	Yutong (Mary) Dai	HAIGIS	MET-mediated Activation of GUK1 is a Common Mechanism of Acquired Resistance Across Oncogenic Drivers in Lung Cancer
60	Marco Campisi	BARBIE	Integrative profiling of primary and microphysiological tumor environments unveils a STING-mediated vascular checkpoint modulating NK cell immunity
61	Radhika Koranne	HATA	Decoding tumor intrinsic and stroma related drug resistance in EGFR mutant NSCLC
62	Chendi Li	HATA	Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induced genomic instability and mitotic cell death
63	Tanvi Saxena	SLACK	TRIDENT : a novel long non-coding RNA required for efficient DNA damage response in NSCLC
64	Monica Mesa Perez	MOTAMEDI	Role of SUV39H1/H2 in HIF-induced epithelial-to-mesenchymal transition (EMT).
65	Christine Goglia	ADELMAN	Probing Compensatory Mechanisms Following Inhibition of SWI/SNF
66	Esin Isik	BURNS	Investigating the intersection of LINE-1 retrotransposition and DNA replication
67	Gregory Brunette	PELLMAN	Haplotype-resolved genome reconstruction reveals a structural basis for Barr body dysregulation in cancer
68	Nataliia Serbyn	PELLMAN	Developing a Model of Chromoplexy to Investigate Catastrophic Cancer Genome Rearrangements
69	Fajinder Ubhi	PELLMAN	Defining mechanisms contributing to cancer genome complexity
70	Hu Jin	PARK	Unmixing Composite Mutational Signatures through Explicit Modeling of Correlations
71	Mohammad Asif Khan	SANDER	Deep sequential modeling of longitudinal diagnostic and medication codes for the prediction of pancreatic cancer risk

2024 Ludwig Retreat Posters

AFTERNOON, continued			
72	Jun Nishida, Vaciry Li	POLYAK	Spatial epigenetic preference and vulnerability of triple-negative breast cancer brain metastases
73	Marco Seehawer	POLYAK	Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3
74	Sonu Subudhi	JAIN	Single nutrient availability is insufficient to broadly predict tissue-specific metabolic dependency of metastases
75	Heena Kumra	JAIN	Mutant p53 exploits enhancers in an NF-kB dependent manner to elevate Cxcl1 gene expression and impair the efficacy of immune checkpoint inhibitors in pancreatic cancer
76	Igor Gomes dos Santos	JAIN	scRNAseq reveals exercise reprograms tumor endothelial cell cycle states and reduces intratumoral angiotensin
77	Ashwin Kumar	JAIN	Targeting B Lymphocytes to Improve Therapeutic Outcomes for Pediatric Medulloblastoma
78	Somin Lee	JAIN	Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma
79	Taylor Uccello	JAIN	Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma.
80	Annie Hsieh	HAIGIS	Widespread Neuroanatomical Integration and Distinct Electrophysiological Properties of Glioma-Innervating Neurons
81	Wonsang Hwang	EVANS	Highly Multiplexed Biomarker Imaging Platform by high-speed fluorescence lifetime imaging system
82	Abigail Miller	GICHOWSKI	Identifying Promising New Drug Combinations for MPNSTs
83	Weiyi Xu	BRUGGE	Evaluate therapeutic approaches to enhance the efficacy of MEK inhibitor and BCL-2/xL combinations in preclinical PDX models
84	Harrison Chong	BAR-PELED	Drugmap: A quantitative pan-cancer analysis of cysteine ligandability.
85	Stefan Harry	BAR-PELED	Systematic Targeting of Protein Complexes with Molecular COUPLrs